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Familial hypercholesterolaemia (FH) is an inherited autosomal dominant disorder resulting from defects 
in the low-density lipoprotein receptor (LDLR), in the apolipoprotein B (APOB) or in the proprotein 
convertase subtilisin/kexin type 9 (PCSK9) genes. In the majority of the cases FH is caused by mutations 
occurring within LDLR, while only few mutations in APOB and PCSK9 have been proved to cause 
disease. p.(Arg3527Gln) was the first mutation in APOB being identified and characterized. Recently 
two novel pathogenic APOB variants have been described: p.(Arg1164Thr) and p.(Gln4494del) showing 
impaired LDLR binding capacity, and diminished LDL uptake. The objective of this work was to analyse 
the structure of p.(Arg1164Thr) and p.(Gln4494del) variants to gain insight into their pathogenicity. 
Secondary structure of the human ApoB100 has been investigated by infrared spectroscopy (IR) and 
LDL particle size both by dynamic light scattering (DLS) and electron microscopy. The results show 
differences in secondary structure and/or in particle size of p.(Arg1164Thr) and p.(Gln4494del) variants 
compared with wild type. We conclude that these changes underlie the defective binding and uptake 
of p.(Arg1164Thr) and p.(Gln4494del) variants. Our study reveals that structural studies on pathogenic 
variants of APOB may provide very useful information to understand their role in FH disease.
Lipoproteins play important physiologic roles in cellular function and regulation of metabolic pathways. 
Apolipoprotein B-100 (ApoB100) are scaffolds of low-density lipoprotein (LDL) particles that are the major nat-
ural transporter of cholesterol and phospholipids, acting as a constant supply of cholesterol for peripheral tissues 
and cells1. ApoB100 contains multiple lipid-associating regions2 to adopt the required structure for binding to 
the LDL receptor (LDLR). Familial hypercholesterolaemia (FH) is a common genetic disorder characterized by 
elevated circulating LDL cholesterol, tendon xanthomas, and premature coronary heart disease3–6. Mutations in 
LDLR are the most common cause of FH, while mutations in APOB and PCSK9 are rare common causes of FH7. 
So far, only a few mutations have been reported and characterized as functionally defective in APOB3,8–12. The 
most common mutation found in APOB is a single amino acid substitution of arginine for glutamine at position 
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3527 (p.(Arg3527Gln)), which markedly reduces the affinity for the LDLR10,11. It has been described that the 
highly conserved receptor binding-site is stabilized by the interaction of Arg3527 with Trp4396, and as mentioned 
above, replacement of Arg3527 by a Gln impairs receptor recognition3,10. Other pathogenic alterations have been 
described, p.(Arg3507Trp), p.(Arg3558Cys), p.(Trp4396Tyr), and recently our group described and characterize 
two novel mutations, p.(Arg1164Thr) and p.(Gln4494del), located in exon 22 and 29, respectively8. Strikingly 
none of these alterations reside in the consensus region of the ApoB100/LDLR binding or in the region postulated 
by Krisko and Etchebest13. Hence, structural characterization of APOB pathogenic variants would improve our 
understanding of both ApoB100 structure-function relationship and mechanisms of interaction with LDLR. The 
extraordinary size of ApoB100, which is a monomeric protein formed by 4,536 amino acids14, is thus a challenge 
for structural studies. LDL surface is surrounded by a single copy of ApoB100, with some regions rich in β -type 
structures embedded in the lipid domain of the particle15,16, while residues involved in LDLR binding are exposed 
to the medium16. It has been suggested that ApoB100 is composed of globular domains connected by flexible 
chains that stabilize the structure of the protein-lipid complex17,18. Analysis of the sequence suggests that ApoB100 
contains five distinct alternating α -helical and β -sheet domains: NH- β α 1-β 1-α 2-β 2-α 3-COOH with different 
lipid binding affinities19,20. Currently, no high-resolution image of any ApoB100 domains is available and different 
attempts have been made to elucidate LDL:ApoB structure. Among them are included, small angle neutron scatter-
ing of lipid-free ApoB100 which describes the modular nature of the protein, with ordered domains connected by 
flexible linkers21; small-angle X-ray scattering which models the LDL core at low-resolution22, and cryomicroscopy 
for single particle reconstruction23. Infrared (IR) spectroscopy complements the information obtained by other 
methodologies, providing information related to size and density of LDL and, also about the secondary structure 
content of ApoB10024,25. Therefore, IR spectroscopy is suitable to have a rapid estimation whether an APOB variant 
produce significant changes in the overall structure of lipoprotein particle.
In the current study we have analysed the particle size of LDL carrying wt ApoB100, and from heterozy-
gote patients carrying p.(Arg3527Gln) (c.10580G> A), p.(Arg1164Thr) (c.3491G>C) and p.(Gln4494del) 
(c.13480_13482delCAG) variants by dynamic light scattering (DLS) and electron microscopy (EM) and their 
secondary structure by IR spectroscopy. We have found differences both in particle size and in the ApoB100 
secondary structure between the mutant particles compared with wt ApoB100 particles that may underlie the 
defective binding and uptake of LDL carrying these ApoB100 variants leading to FH.
Results
Impaired binding capacity of p.(Arg1164Thr) and p.(Gln4494del) ApoB100 variants. As described 
before by Alves and colleagues8, binding of p.(Arg3527Gln), p.(Arg1164Thr) and p.(Gln4494del) in lymphocytes 
resulted diminished when compared with wt ApoB100 (Fig. 1). LDL uptake showed impaired LDL uptake by 
the pathogenic variants of about 50% compared with wt (Fig. 1). Deficient LDL uptake of the LDL containing 
ApoB100 variants by HepG2 cells was also confirmed, being LDL uptake similar to that determined in human 
lymphocytes (Fig. 1).
Next, we confirmed the impaired binding capacity of p.(Arg3527Gln), p.(Arg1164Thr) and p.(Gln4494del) 
variants with the U937 cells proliferation assay which is a reference method to determine functional assays in 
APOB26. Cells growing in the presence of LDL carrying p.(Arg3527Gln), p.(Arg1164Thr) or p.(Gln4494del) variants 
showed ~1/3 growth compared with wt LDL (Fig. 2).
Figure 1. Binding of FITC-LDL in lymphocytes and uptake of FITC-LDL in lymphocytes and HepG2. 
Binding of FITC-LDL was assessed by incubation of lymphocytes with 20 μ g/mL labelled-LDL for 4 h at 4 °C. 
For analysis of FITC-LDL uptake, lymphocytes or HepG2 cells were incubated for 4 h at 37 °C with 20 μ g/
mL FITC-LDL. 10,000 cells were acquired in a FACScalibur. The values represent the mean of triplicate 
determinations (n = 3); error bars represent ± SD. *p < 0.025 compared with wt ApoB100 (Student’s t-test, two 
tailed).
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LDL size analysis. Peak diameters of LDL particle carrying wt ApoB100, p.(Arg3527Gln), p.(Arg1164Thr) 
and p.(Gln4494del) were determined by DLS (Fig. 3A). The mean LDL diameter of the wt ApoB100-LDL was 
29.1 ± 0.2 nm and, the diameters of p.(Arg3527Gln), p.(Arg1164Thr) and p.(Gln4494del) -LDL were 27.8 ± 0.3 nm, 
27.9 ± 0.6 nm and 25.2 ± 0.9 nm, respectively.
LDL carrying wt ApoB100 or p.(Arg3527Gln), p.(Arg1164Thr) or p.(Gln4494del) variants were examined by 
NS-EM for morphology and size estimation. All images examined were approximately circular, consistent with a 
spherical shape (Fig. 3B,C). For wt LDL, 75% of the selected 1600 particles were in the diameter range of 27–31 nm, 
with the peak population (21%) at 29 nm (Fig. 3D). However, electron micrographs of patients LDL with apoB 
variants p.(Arg3527Gln), p.(Arg1164Thr) and p.(Gln4494del) showed smaller diameters. Accordingly, for p.(Arg-
3527Gln) and p.(Arg1164Thr) variants most of the particles (~78%) were in the diameter range of 25–29 nm, with 
the peak population (~ 20%) at 27 nm (Fig. 3D). However, electron micrographs of p.(Gln4494del)-LDL showed 
that most (81%) of the selected particles were between 24–27 nm in diameter with the peak population (77%) at 
25.5 nm (Fig. 3D).
Differences in secondary structure content among ApoB100 variants. In order to analyse by IR 
spectroscopy the effects produced by p.(Arg3527Gln), p.(Arg1164Thr) and p.(Gln4494del) variants in ApoB100 
structure, amide I band of each sample was individually fitted considering the component band position obtained 
from Fourier derivation and deconvolution, as previously described25. These component bands have been assigned 
to several secondary structures as α -helix, β -turns, sheets or strands, and other unordered structures, usually called 
random, that typically appear around 1656, 1670, 1630, 1617 and 1642 cm−1 in deuterated media, respectively16,24. 
In LDL, β -strands are defined as segments embedded inside the particle monolayer, which are characterized by 
a band at a lower frequency than canonical extended structure (16). The mean secondary structure composition 
obtained for wt ApoB100 was characterized by a high content in β -structures (> 50%) with α -helix content of about 
20% (Table 1), in agreement with previous IR studies24,25. ApoB100 p.(Arg3527Gln) variant showed a reduced con-
tent in β -strands (around 3%) with slight increase in α -helixes (2%), similarly to that occurring in p.(Gln4494del) 
variant in which deletion of Gln at 4494 position produced a clear change in amide I band shape (Fig. 4) mainly 
resulting in a decrease of β -strands, from 22% to 15%, and in approximately 4% increase in α -helix contribution 
(Table 1). In contrast, p.(Arg1164Thr) variant showed an amide I band decomposition similar to wt (Table 1), as 
expected from the similarity of their band shapes (Fig. 4).
Discussion
FH is one of the most prevalent genetically inherited disorders that leads to greatly increased LDL levels over a 
lifetime and development of early coronary artery disease27. The mechanisms underlying the process of atheroscle-
rotic changes of the vessel wall have been extensively addressed both clinically and experimentally and, searching 
the APOB gene for new pathogenic variants has disclosed few alterations reported as functionally defective3,8–12,28.
In the present work we sought to understand the loss of functionality previously shown for p.(Arg1164Thr) 
and p.(Gln4494del) ApoB variants8. We have used a biophysical approach to determine LDL binding, uptake, 
particle size and secondary structure of LDL containing p.(Arg3527Gln), p.(Arg1164Thr) and p.(Gln4494del) 
ApoB variants. A major limitation in the present study is that LDL characterization is based on samples obtained 
from heterozygous mutation carriers. Nevertheless, the validity of this work is strengthened by previous in vivo 
studies showing that in heterozygous patients, particles carrying functional-defective ApoB100 accumulate in 
plasma, for example, p.(Arg3527Gln) mutant:wild-type LDL ratio was shown to be ~70:3029 and p.(Arg50Trp) 
mutant:wild-type ratio ~75:2528. In this study, the ~50% decreased binding and uptake of LDL together with 
Figure 2. U937 cell proliferation assay with wt or LDL containing ApoB-100 variants. Cells were incubated 
for 48 h with LDL and proliferation was assessed by CellTiter 96wAQueous Non-Radioactive Cell Proliferation 
Assay. The values represent the mean of triplicate determinations (n = 3); error bars represent ± SD. *p < 0.025 
compared with wt ApoB100 (Student’s t-test, two tailed).
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the ~2/3 reduced proliferation of U937 cells when incubated with LDL from heterozygous patients containing 
p.(Arg1164Thr) or p.(Gln4494del) variants shows an impaired LDL/LDLR recognition in saturable conditions.
It has been suggested that in patients carrying p.(Arg3527Gln) variant, the impaired removal of LDL from 
plasma promotes the formation of small dense LDL particles (sdLDL)10. In the present work, LDL particles obtained 
from heterozygous patients carrying p.(Arg3527Gln) or p.(Arg1164Thr) variants show a main population of par-
ticles of ~27 nm, significantly smaller than the ones carrying wt ApoB100 (~29 nm) and furthermore, the reduced 
Figure 3. Different LDL size distribution among ApoB-100 variants. (A) Size distribution of isolated LDL 
carrying wt, p.(Arg3527Gln), p.(Arg1164Thr) and p.(Gln4494del) variants determined by DLS; (B) electron-
micrographs of wt, p.(Arg3527Gln), p.(Arg1164Thr) and p.(Gln4494del) variants at low resolution showing 
a homogeneus particle population; (C) selected individual LDL particles at higher magnification showing 
and (D) Frequency histograms showing particle size distribution of wt, p.(Arg3527Gln), p.(Arg1164Thr) 
and p.(Gln4494del) variants. Particle size was determined as described in Materials and Methods. LDL size 
distribution in D was measured as Feret diameter calculated from 1600 particles.
Structure wt ApoB100 p.(Arg3527Gln) p.(Arg1164Thr) p.(Gln4494del)
β -Turn 11.0 ± 0.7 12.0 ± 0.8 11.3 ± 0.5 13.4 ± 0.7
α -helix 19.8 ± 1.1 21.6 ± 1.4* 19.2 ± 0.5 24.2 ± 1.4*
Random 21.7 ± 0.4 22.4 ± 0.6 21.6 ± 0.2 23.6 ± 0.5
β Sheet 25.8 ± 0.3 25.5 ± 0.2 25.3 ± 0.4 24.3 ± 2.1
β Strand 21.7 ± 1.8 18.6 ± 1.7* 22.6 ± 1.0 14.5 ± 2.3*
Table 1.  Secondary Structure content of LDL carrying wt, p.(Arg3527Gln), p.(Arg1164Thr) or 
p.(Gln4494del) ApoB100 variants. Values shown represent the mean ± standard deviation. *p < 0.01 
compared with wt ApoB100.
www.nature.com/scientificreports/
5Scientific RepoRts | 5:18184 | DOI: 10.1038/srep18184
size is even more pronounced in LDL harbouring p.(Gln4494del) ApoB100, with a mean diameter of ~25 nm. Thus, 
the smaller size found in LDL carrying p.(Arg1164Thr) and p.(Gln4494del) raises the possibility that delipidation 
processes may occur in vivo. It has been shown that the longer residence of LDL in blood allows an extensive activity 
of certain enzymes such as hepatic lipase (HL) and, cholesterol ester transfer protein (CETP)30,31. In fact, in vitro 
studies reveal that lipoprotein lipase (LPL) and HL induce alterations in LDL composition mainly characterized 
by a substantial reduction in the core triglyceride content32. It has also been shown that the sequential effects of 
lipid transfer and lipolysis promote dramatic changes in the mean size of plasma LDL favouring the formation 
of sdLDL33.
Adding onto that, the mutation itself can distort the structure of the binding domain of ApoB100 as described 
for p.(Arg3527Gln) mutation34. The belt conformation of ApoB100 that surrounds the LDL particle is maintained 
by interaction of Arg3527 with Trp439615, which stabilizes two clusters of basic amino acids ensuring the binding of 
ApoB100 to LDLR35. It has been proposed that replacement of the Arg3527 promotes a conformational change in 
ApoB100 causing a rearrangement of a number of charged residues rather than loss of a single receptor-interactive 
residue36. The maintenance of these clusters could also be hampered in the case of p.(Gln4494del) variant because 
the amino acid deletion moves forward one position into the following amino acid. Therefore, the distortion 
introduced by p.(Gln4494del) may have a central role in the defective binding and the formation of smaller LDL 
particles. The analysis of these LDL by IR spectroscopy shows marked differences in the secondary structure of 
p.(Arg3527Gln) and p.(Gln4494del) compared with wt, their β -strands content being lower while their random 
and α -helix structure contributions slightly higher. It has been described that the reduced content of β -strands may 
be related with smaller LDLs37 and that changes in the intensity and width of the β -strands band detected by IR 
spectroscopy might be related to more atherogenic LDL25. Although, the differences in the % structure may seem 
small, considering the big size of ApoB100, these results imply a huge structural rearrangement that likely affects 
the affinity for LDLR. Therefore, these structural changes may account for the impaired affinity of LDL carrying 
p.(Arg3527Gln) or p.(Gln4494del).
LDL particle diameter and ApoB100 conformation have implications for the binding affinity of ApoB100 to the 
receptors38 thus the observed differences in one of these parameters, if not both, explain the defective activity of 
the ApoB100 variants characterized in this work. It is noteworthy that p.(Arg1164Thr) mutation barely modifies 
ApoB100 structure despite the reduced uptake of this lipoprotein, suggesting that Arg 1164 residue is important 
for LDL interaction with LDLR.
Figure 4. Amide I band decomposition of LDL carrying wt, p.(Arg3527Gln), p.(Arg1164Thr) or 
p.(Gln4494del) ApoB100 variants. The spectra were obtained in D2O buffer at 37 °C as described in Materials 
and Methods.
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We conclude that changes found in particle size and/or secondary structure composition of ApoB100 underlie 
the defective binding and uptake of p.(Arg3527Gln), p.(Arg1164Thr) and p.(Gln4494del) variants. The structural 
analysis of these LDL carrying ApoB variants helps to understand their defective binding to LDLR, and remarks 
the importance of residues outside the postulated LDLR binding domain for ApoB100 to adopt a correct struc-
ture. In vitro experiments mimicking delipidation processes of lipoproteins are still in progress in our laboratory 
to elucidate how these processes affect both particle size and ApoB100 structure and will help to correlate these 
factors with LDL binding capacity.
Materials and Methods
Study samples. Carriers of variants under study and normolipidaemic subjects were asked to provide a new 
blood sample to repeat previous ApoB studies and to perform the new structure analysis assays8. Serum was fro-
zen at − 80 °C until the start of the experiments. Peripheral blood lymphocytes were isolated at room temperature 
using a density gradient method as described before39. The FH patients are included in the Portuguese FH Study, 
the study protocol was approved by the ethics committee of CEIAB of the Basque Country University and by the 
National Institute of Health Ethics Committee (Portugal), the methods were carried out in accordance with the 
approved guidelines. All participants have signed the written informed consent.
Lipoprotein isolation, characterization and labeling. LDL (1.019–1.063 g/mL) was isolated from human 
serum by density gradient ultracentrifugation40. Protein content of LDL was determined according to Lowry 
protein assay41, triglycerides (TG) and LDL cholesterol (LDL-C) were determined by direct enzymatic procedures 
using the reagent kit supplied by BioSystem (BioSystem S.A., Barcelona, Spain). LDL was labelled with FITC as 
previously described40.
Lymphocyte LDL uptake and binding assay. Human lymphocytes were cultured in 24-well culture plates 
(2 × 105 cells/well) for 72 h in lipoprotein-deficient serum and stimulated with anti-CD3/CD28 beads as previously 
described39 to obtain maximum upregulation of LDLR. LDL uptake was determined in lymphoblast incubated for 
4 h with 20 μ g/mL FITC–LDL at 37 °C and LDL binding was determined incubating the cells with FITC-LDL at 
4 °C. After incubation with FITC-LDL, lymphocytes were washed twice in PBS-1%BSA, fixed on 4% formaldehyde 
for 10 min and washed again twice with PBS-1%BSA. Fluorescence intensities were measured by flow cytometry 
in a FACSCalibur Flow cytometer and fluorescence of 10,000 events was acquired for data analysis as described 
before39. The results were expressed as the mean fluorescence of activated gated cells, selected in a forward versus 
side-scatter window. LDLR genotype (wt) of lymphocyte donors was ascertained by sequencing.
LDL uptake by HepG2 cells. FITC-labeled LDL uptake by HepG2 cells was also determined. HepG2 cells 
were grown in monolayer at 37 °C in DMEM with 10% (v/v) foetal bovine serum (FBS, Invitrogen), 100 U/mL 
penicillin/streptomycin. 5 × 104 cells were seeded in 24-well culture plates for 24 h then FITC–LDL uptake was 
performed as described above for lymphocytes.
U937 cells proliferation assay. U937 cells (ATCC CRL-1593.2TM) were grown in RPMI with ampicillin/
streptomycin and 10% FBS in a 75-cell culture flask, at 2 × 105 viable cells/mL at 37 °C in a humidified atmosphere 
of 5% CO2. Before proliferation assay, cells were seeded in 96-well culture plates for 24 h in RPMI containing 10% 
LPDS and the assay was started by adding 2 μ g/mL LDL. The cells were further incubated for 48 h at 37 °C allowing 
cell growth. U937 cell proliferation was determined by CellTiter 96wAQueous Non-Radioactive Cell Proliferation 
Assay as previously described8. The proliferation rate in the presence of LDL carrying wt ApoB100 or the three 
different mutations has been expressed as fold increment of cellular growth compared with basal growth of cells 
without added LDL. LDL samples were conditioned for IR measurements as previously described25.
LDL size determination. LDL size was determined from 1 mg/mL protein samples by dynamic light scatter-
ing in a Nano-S Zetasizer (Malvern Instruments, UK) as previously described42. For the study, all LS measurements 
were performed at 37 °C in triplicate, with 25 runs of 10 seconds each, using a 173° backscatter detection. The 
detection limit of the assay for zetasizer instrument used in the present study was 0.3 nm to 10 μ m. Viscosity and 
refractive index of PBS as the dispersant were applied to standard operating protocol prior to size determination. 
The data were analyzed by zetasizer family software
LDL size determination by negative stain electron microscopy (NS-EM). For negative stain elec-
tron microscopy (NS-EM) a 10 μ L drop of lipoprotein solution (100 μ g/mL) was placed on a glow-discharged 
thin carbon-coated 300-mesh copper grid (Cu-300CN; Pacific Grid-Tech, San Francisco, CA). After ~1 min, the 
excess solution was removed by blotting with filter paper. The grid was washed three times by briefly touching the 
surface of the grid with a drop (~30 μ L) of deionized water on Parafilm and then blotted dry with filter paper. The 
touching and blotting steps were performed, each with a clean drop of deionised water. One drop (~30 μ L/drop) 
of 1% (w/v) uranyl acetate (UA) (pH 4.6) solution were applied on Parafilm, and the excess solution was removed 
by blotting similarly. The grid remained in contact with the last UA drop with the sample side down for 1–3 min 
in the dark before excess stain was removed and the sample was air dried at room temperature.
Particle size was determined by measuring Feret diameter, individual particle images were selected, picked 
automatically and manually checked to remove overlapping or damaged particles. More than 1600 particle images 
from micrographs of each condition were used for statistical analysis of particle size distribution.
Infrared spectroscopy. LDL samples were conditioned for IR measurements as previosly described25. Briefly, 
isolated LDL particlces were concentrated on Microcon centrifugal filters (Millipore) to a final concentration of 
8–10 mg/mL and extensively dialyzed against deuterated PBS buffer at 4 °C in closed container. The buffer was 
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changed several times until completed H2O-D2O exchange was achieved. Samples were placed in 25 μ m carved 
calcium fluoride windows. Infrared spectra were recorded at 37 °C in a Nicolet Nexus 5700 spectrometer equipped 
with a MCT detector using a Peltier cell (TempCon, Bio Tools). Buffer subtraction was performed by using the 
buffers of the last dialysis step as reference and analyzed by Fourier deconvolution and derivation in order to define 
the number and position of constituent bands of the amide I band. Baseline corrected spectra were fitted using 
two step procedure as previously described43 and considering Gaussian band shape for all component bands24.
Statistical analysis. All measurements were independently performed at least 3 times, with n= 3 unless 
otherwise stated, and results are presented as mean ± s.d. Levels of significance were determined by a two-tailed 
Student’s t-test, and a confidence level of greater than 95% (p< 0.05) was used to establish statistical significance.
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